Company Overview and News
Hindustan Oil Exploration Company Ltd (HOEC) on Wednesday said it has signed a revenue sharing contract with the Government for an oil and gas block in Assam that it had won in the first round of Open Acreage Licensing Policy (OALP).
IOC 533106 HINDOILEXP OIL 530965 500186
Paving the way for the next wave of hydrocarbon explorations in the country, the government on Monday signed agreements with the winners of the 55 blocks offered under the Open Acreage Licensing Policy (OALP), a critical part of the Hydrocarbon Exploration Licensing Policy (HELP) launched in March 2016. Vedanta Cairn has been awarded 41 blocks offered and Oil India has been awarded 9 blocks. ONGC has won 2 blocks.
533106 VED HINDOILEXP 500325 530075 OIL RELIANCE RIGD SELAN 500186 RLNIY
As much as Rs 5,900 crore of investment has been committed in 55 oil and gas exploration areas awarded under India's maiden open acreage auction, OALP-1, Oil Minister Dharmendra Pradhan said.
HINDOILEXP 500325 BPCL 500547 BRQPY RELIANCE RIGD 500186 RLNIY
Mumbai: Invenire Energy Pvt. Ltd will likely acquire Tata Petrodyne Ltd (), the upstream oil and gas business of the diversified Tata Group, said three people aware of the matter. Invenire Energy is backed by a consortium of private equity firms for the potential deal, the people who didn’t wish to be named said in an interview. The transaction is expected to close shortly, they said without disclosing the estimated value of the deal.
TATAPOWER CAIRN CWNQY 500470 HINDOILEXP TTST 532792 TATASTEEL TATLY TPCL 500400 500570 TATAMOTORS 500186 TTM
New Delhi : Mining mogul Anil Agarwal-led Vedanta has bagged 41 out of 55 oil and gas exploration blocks offered in India’s maiden open acreage auction, upstream regulator DGH said on Tuesday.
HINDOILEXP BPCL 500547 BRQPY 500186
The government has notified a new policy requiring state owned Oil and Natural Gas Corp (ONGC) and Oil India Ltd (OIL) to pay royalty and cess tax only to the extent of their equity holding in certain pre-1999 oil and gas fields.
533106 HINDOILEXP CNE OIL CRNZF 500186 CRNCY
New Delhi: Anil Agarwal-led Vedanta Ltd is likely to bag as many as 40 oil and gas exploration blocks in India’s maiden open acreage auction, people familiar with the matter said on Tuesday.
HINDOILEXP 532792 500325 RELIANCE RIGD 500186 CAIRN CWNQY RLNIY
Anil Agarwal-led Vedanta Ltd is likely to bag as many as 40 oil and gas exploration blocks in India's maiden open acreage auction, official sources said today. An Empowered Committee of Secretaries (ECS) has cleared award of blocks offered in OALP-1, bidding for which closed on May 2, they said.
HINDOILEXP 532792 500325 RELIANCE RIGD 500186 CAIRN CWNQY RLNIY
Shares of Hindustan Oil Exploration Company (HOEC) added 4.7 percent intraday Friday as company completed two well re-entry and side track drilling campaign which commenced in April 2018.
The boards of Alkali Metals, Bajaj Hindusthan, Gallant Ispat, Gallant Metal, Hindustan Oil Exploration, JK Cement, LGB Forge, Omaxe Auto, PTC India Financial, Vinati Organics and Vardhman Textiles will meet on Saturday for Q4/FY18 results for the period ended March 2018. The JK Cement board will also consider issuance of NCDs on private placement. SORIL Holdings and Ventures will consider a preferential issue/price for equity shares to foreign investors.
VTL 533007 533029 HINDOILEXP 500820 LGBFORGE ALKALI 524200 502986 VINATIORGA ASIANPAINT 500186
Mumbai: Tata Petrodyne Ltd, which has put up its six oil and gas blocks for sale, is yet to find interest from buyers, two people aware of the matter said.
HINDOILEXP 532792 TATAPOWER TPCL 500400 500186 CAIRN CWNQY
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...